EMA Issues First EU Guidance for Clinical Trials During Public Health Emergencies
核心洞察
The European Medicines Agency (搜索) has released draft guidance for conducting clinical trials during public health emergencies, marking the first EU guidance to reflect current legislative frameworks and lessons learned from COVID-19 (搜索).
The guidance emphasizes prioritizing well-designed clinical trials over compassionate use programs to generate robust evidence for regulatory decision-making during emergencies.
New regulatory mechanisms are proposed to accelerate trial authorization and modifications during PHEs, with sponsors encouraged to seek advice from EMA's Emergency Task Force (搜索).
The European Medicines Agency (搜索) (EMA) has released draft guidance for sponsors conducting clinical trials during public health emergencies (PHEs), establishing the first comprehensive EU framework for maintaining research continuity during crisis situations. Published through the Accelerating Clinical Trials in the European Union (ACT EU) initiative, the guidance addresses both new and existing studies during emergency conditions.
Regulatory Framework and Lessons from COVID-19
This guidance represents the first EU document on PHEs to reflect the current legislative framework and incorporates guidelines from the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (搜索) (ICH) developed following the COVID-19 (搜索) pandemic. The document recommends a harmonized approach to ensure clinical trials can be initiated, adapted, and continued efficiently and safely when public health emergencies arise.
A critical insight from the pandemic experience is highlighted in the guidance: "A key lesson learnt from the Covid-19 (搜索) pandemic is that small, isolated clinical trials or compassionate use programmes in individual Member States may not generate sufficiently robust evidence for clear medical and public health recommendations. This underlines the need to prioritise the inclusion of trial participants in well-designed clinical trials over off-label or compassionate use in order to strengthen the scientific basis for decision making."
Accelerated Authorization Mechanisms
The guidance proposes regulatory mechanisms aimed at accelerating the authorization of new clinical trials and the approval of modifications to ongoing trials during PHEs. Sponsors are encouraged to seek scientific advice from EMA's Emergency Task Force (搜索) (ETF (搜索)) to ensure trials are well-designed, efficient, and capable of delivering meaningful data for regulatory assessment.
For new studies, the EMA emphasizes that "timely generation of robust and reliable evidence is essential" and that "trial design, procedures and oversight" should be "fit for purpose and take into account the nature and scale of the emergency."
Adaptations for Ongoing Studies
For studies that were already ongoing before a PHE, sponsors are asked to consider whether protocols can be amended, site visits reduced or decentralized with technology, along with other considerations to ensure patients are protected during trials. The guidance allows for situations in which trial patients can be transferred across investigational sites, recognizing that adapted procedures or alternative approaches may be required due to the specific challenges posed by PHEs.
Regulatory Context and Timeline
The US Food and Drug Administration (搜索) (FDA) previously released guidance on the conduct of clinical trials in major disruptions due to disasters and PHEs in September 2023, providing a regulatory precedent for the EMA's approach. The draft guidance document is open for public consultation until April 30, 2026, allowing stakeholders to provide input on the proposed framework.